HUTCHMED (China) Limited
HCMHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong,. At a $1.93B market cap, HUTCHMED (China) Limited ranks as a small-cap company within healthcare. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Market Cap
$1.93B
Beta
0.38
P/E (TTM)
4.24
P/E (Fwd)
21.62
EPS (TTM)
$2.65
EPS (Fwd)
$0.52
ROE
45.3%
ROA
-1.6%
Cash
$1.37B
Total Debt
$97.9M
Free CF
-$54.0M
52W Change
-19.1%
Annual Financials
Cash vs Debt
With $1.37B in cash and $97.9M in debt, HCM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$54.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 45.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $426.4M to $548.5M.
With a beta below 0.7, HUTCHMED (China) Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, HCM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing HCM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.